PURPOSE: To evaluate circulating and lesional CD4(+) and CD8(+) cells belonging to Th1, Th2, and Th17 patterns as well as IL-10(+) cells before and after a 12-week lasting course with etanercept or acitretin in patients with psoriasis. METHODS: 15 patients were given etanercept 50 mg twice weekly and 15 patients acitretin 0,4 mg/kg/day, both for 12 weeks. At the baseline and at the end of the treatment, blood and skin samples were taken to investigate IL-4, IL-8, IL-10, IL-17, and IFN-γ-producing CD4(+) and CD8(+) cells. As controls, 10 healthy controls (HC) and 6 atopic dermatitis (AD) patients were included into the study. RESULTS: Psoriasis patients showed augmented IL-17- and IL-8-producing CD4(+) cells in the blood than HC and AD patients. In the skin lesions, IL-17(+) cells were more represented in psoriasis than in AD, while the number of IL-4-producing cells was reduced in psoriasis patients than in AD ones. Etanercept was able to significantly reduce the number of IL-17- and IL-8-producing CD4(+) and CD8(+) cells both in skin and blood, as well as to augment the proportion of IL-10-producing CD4(+) cells in the skin of psoriatic patients, while acitretin was not. CONCLUSIONS: Our results confirmed the role of Th17 cells in the pathogenesis of psoriasis. Etanercept, but not acitretin, was able to downregulate the Th17 pathway and to increase the percentages of IL-10-producing cells in the skin.
PURPOSE: To evaluate circulating and lesional CD4(+) and CD8(+) cells belonging to Th1, Th2, and Th17 patterns as well as IL-10(+) cells before and after a 12-week lasting course with etanercept or acitretin in patients with psoriasis. METHODS: 15 patients were given etanercept 50 mg twice weekly and 15 patientsacitretin 0,4 mg/kg/day, both for 12 weeks. At the baseline and at the end of the treatment, blood and skin samples were taken to investigate IL-4, IL-8, IL-10, IL-17, and IFN-γ-producing CD4(+) and CD8(+) cells. As controls, 10 healthy controls (HC) and 6 atopic dermatitis (AD) patients were included into the study. RESULTS:Psoriasispatients showed augmented IL-17- and IL-8-producing CD4(+) cells in the blood than HC and ADpatients. In the skin lesions, IL-17(+) cells were more represented in psoriasis than in AD, while the number of IL-4-producing cells was reduced in psoriasispatients than in AD ones. Etanercept was able to significantly reduce the number of IL-17- and IL-8-producing CD4(+) and CD8(+) cells both in skin and blood, as well as to augment the proportion of IL-10-producing CD4(+) cells in the skin of psoriaticpatients, while acitretin was not. CONCLUSIONS: Our results confirmed the role of Th17 cells in the pathogenesis of psoriasis. Etanercept, but not acitretin, was able to downregulate the Th17 pathway and to increase the percentages of IL-10-producing cells in the skin.
Authors: Hideaki Sugiyama; Rolland Gyulai; Eiko Toichi; Edina Garaczi; Shinji Shimada; Seth R Stevens; Thomas S McCormick; Kevin D Cooper Journal: J Immunol Date: 2005-01-01 Impact factor: 5.422
Authors: J F Schlaak; M Buslau; W Jochum; E Hermann; M Girndt; H Gallati; K H Meyer zum Büschenfelde; B Fleischer Journal: J Invest Dermatol Date: 1994-02 Impact factor: 8.551
Authors: Lisa C Zaba; Judilyn Fuentes-Duculan; Narat John Eungdamrong; Maria Veronica Abello; Inna Novitskaya; Katherine C Pierson; Juana Gonzalez; James G Krueger; Michelle A Lowes Journal: J Invest Dermatol Date: 2008-07-17 Impact factor: 8.551
Authors: Lisa C Zaba; Irma Cardinale; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; Mayte Suárez Fariñas; Judilyn Fuentes-Duculan; Inna Novitskaya; Artemis Khatcherian; Mark J Bluth; Michelle A Lowes; James G Krueger Journal: J Exp Med Date: 2007-11-26 Impact factor: 14.307
Authors: Emiliano Antiga; Veronica Bonciolini; Walter Volpi; Elena Del Bianco; Marzia Caproni Journal: Biomed Res Int Date: 2015-05-18 Impact factor: 3.411
Authors: Joel A Mathews; Alison S Williams; Jeffrey D Brand; Allison P Wurmbrand; Lucas Chen; Fernanda Mc Ninin; Huiqing Si; David I Kasahara; Stephanie A Shore Journal: PLoS One Date: 2014-05-13 Impact factor: 3.240
Authors: Patricia Luz-Crawford; Gabriel Espinosa-Carrasco; Natacha Ipseiz; Rafael Contreras; Gautier Tejedor; Daniel A Medina; Ana-Maria Vega-Letter; Devi Ngo; Eric F Morand; Jérôme Pène; Javier Hernandez; Christian Jorgensen; Farida Djouad Journal: Theranostics Date: 2018-01-01 Impact factor: 11.556